Achilles Therapeutics plc - American Depositary Shares (ACHL)

Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma –

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma –

– Improved VELOS™ manufacturing process delivering higher cNeT doses –

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference:

Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies

– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 –

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash holdings.

NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (“ODD”) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQGNPX) ( Profile ) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (“SCLC”). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.’s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer (“ES-SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC NASDAQ: JAZZNASDAQJAZZ)(NASDAQ: ALXONASDAQALXO and Achilles Therapeutics PLC (NASDAQ: ACHLNASDAQ) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

EQNX::TICKER_START (NASDAQGNPX),(OTCQX:RHHBY),NASDAQ:JAZZNASDAQJAZZ)(NASDAQ:ALXONASDAQALXO,(NASDAQ:ACHLNASDAQ) EQNX::TICKER_END

- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma -

LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June:

- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 -

- New AI module delivers a "Target-to-T cell” approach for revolutionizing the identification and prioritization of targets for personalized antigen approaches -

Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the Notice

- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor -

LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, and Dr. Ed Samuel, EVP, Technical Operations, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 24, 2023, at 11:30am ET / 4:30pm UK.

- Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients -

LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST. The event will be held at the Westin St. Francis Hotel in San Francisco, California.

- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC -

- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy -

- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches -

- Interim update from the ongoing Phase I/IIa trials in advanced NSCLC (CHIRON) and melanoma (THETIS) to be presented at the ESMO Immuno-Oncology Annual Congress 2022 -

Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets

- Secarna's LNAplusTM ASOs have the potential to optimize personalized T cell therapies being developed by Achilles - Secarna's industry-leading antisense oligonucleotide (ASO) platform LNAplusTM enables discovery and research of ASOs against undisclosed targets in the area of immune oncology MUNICH, GERMANY and MARTINSRIED, GERMANY / ACCESSWIRE / November 10, 2021 / Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical